Variant report
Variant | nsv528863 |
---|---|
Chromosome Location | chr2:210088080-210114896 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs4672549 | chr2:210096031-210096032 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
2 | rs537311082 | chr2:210096035-210096036 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs550844944 | chr2:210096051-210096052 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs565560275 | chr2:210096093-210096094 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs567645081 | chr2:210096156-210096157 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs371077588 | chr2:210096157-210096158 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs552975779 | chr2:210096169-210096170 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs140938457 | chr2:210096177-210096178 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs114668929 | chr2:210096184-210096185 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs181606097 | chr2:210096204-210096205 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs184562121 | chr2:210096209-210096210 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
12 | rs561146191 | chr2:210096237-210096238 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs574716907 | chr2:210096252-210096253 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
14 | rs542614233 | chr2:210096285-210096286 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
15 | rs559699492 | chr2:210096330-210096331 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs117852282 | chr2:210096369-210096370 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
17 | rs530313359 | chr2:210096430-210096431 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
18 | rs188529723 | chr2:210096431-210096432 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
19 | rs6757269 | chr2:210096534-210096535 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
20 | rs530984642 | chr2:210096555-210096556 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs566942729 | chr2:210096557-210096558 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs550806410 | chr2:210096606-210096607 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs567857229 | chr2:210096626-210096627 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
24 | rs147832631 | chr2:210096705-210096706 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
25 | rs6760272 | chr2:210096706-210096707 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
26 | rs185224506 | chr2:210096723-210096724 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
27 | rs566487383 | chr2:210096724-210096725 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
28 | rs538322906 | chr2:210096730-210096731 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
29 | rs6745027 | chr2:210096744-210096745 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
30 | rs386654653 | chr2:210096779-210096780 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
31 | rs10932290 | chr2:210096785-210096786 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
32 | rs55732044 | chr2:210096836-210096837 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
33 | rs551190964 | chr2:210096853-210096854 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
34 | rs574598499 | chr2:210096887-210096888 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
35 | rs55689700 | chr2:210096893-210096894 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
36 | rs553056178 | chr2:210096981-210096982 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
37 | rs573172957 | chr2:210096998-210096999 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
38 | rs545026261 | chr2:210097006-210097007 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
39 | rs374835875 | chr2:210097012-210097013 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
40 | rs191163206 | chr2:210097040-210097041 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
41 | rs530953674 | chr2:210097051-210097052 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
42 | rs74375241 | chr2:210097078-210097079 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
43 | rs74392029 | chr2:210097079-210097080 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
44 | rs530303192 | chr2:210097104-210097105 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
45 | rs547288184 | chr2:210097108-210097109 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
46 | rs567085955 | chr2:210097114-210097115 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
47 | rs368866611 | chr2:210097208-210097209 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
48 | rs552250405 | chr2:210097225-210097226 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
49 | rs4516360 | chr2:210097348-210097349 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
50 | rs4450535 | chr2:210097349-210097350 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Ependymoma | 16718352 | CNVD |
Melanoma | 18172304 | CNVD |
Cancer | 16751803 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Acute lymphoblastic leukemia | 21980252 | CNVD |
Breast cancer | 17603634 | CNVD |
Testicular germ cell tumor | 18059402 | CNVD |
Breast cancer | 16272173 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Cancer | 21637783 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Liposarcoma | 21253554 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 21264507 | CNVD |
Embryonal rhabdomyosarcoma | 16790082 | CNVD |
Autism | 16446308 | CNVD |
Autism | 19401682 | CNVD |
Colorectal cancer | 16272173 | CNVD |
Lung cancer | 18438408 | CNVD |
Prostate cancer | 18632612 | CNVD |
Acute myeloid leukemia | 20729466 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Biliary cancer | 20360734 | CNVD |
Breast cancer | 20360734 | CNVD |
Coronary artery disease | 20360734 | CNVD |
Crohn''s disease | 20360734 | CNVD |
Hypertension | 20360734 | CNVD |
Rheumatoid arthritis | 20360734 | CNVD |
Type 1 diabetes | 20360734 | CNVD |
Type 2 diabetes | 20360734 | CNVD |
Urothelial carcinoma | 21177765 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Cervical cancer | 21062161 | CNVD |
Adenoid cystic carcinoma | 18698036 | CNVD |
Non-muscle invasive bladder neoplasm | 19445696 | CNVD |
Non-small cell lung cancer | 21829676 | CNVD |
Autism | 20808228 | CNVD |
Renal cell carcinoma | 18765545 | CNVD |
Ovarian cancer | 19193619 | CNVD |
Non-small cell lung cancer | 18676828 | CNVD |
Oral squamous cell carcinoma | 17134496 | CNVD |
Myofibroblastic sarcoma | 19369631 | CNVD |
Chordoma | 18071362 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Schizophrenia | 18923514 | CNVD |
Schizophrenia | 22241247 | CNVD |
Non-syndromic sensorineural hearing loss | 15273396 | CNVD |
Urothelial cell carcinoma | 18451213 | CNVD |
Acute lymphoblastic leukemia | 22237106 | CNVD |
Developmental delay | 21147756 | CNVD |
Breast cancer | 22522925 | CNVD |
Pancreatic cancer | 17952125 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr2:210096000-210096800 | Enhancers | HUES48 Cell Line | embryonic stem cell |
2 | chr2:210096000-210096800 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
3 | chr2:210096200-210096800 | Enhancers | HUES6 Cell Line | embryonic stem cell |
4 | chr2:210096200-210096800 | Enhancers | iPS-18 Cell Line | embryonic stem cell |
5 | chr2:210096200-210096800 | Enhancers | iPS-20b Cell Line | embryonic stem cell |
6 | chr2:210096800-210100800 | Weak transcription | iPS-15b Cell Line | embryonic stem cell |
7 | chr2:210096800-210101000 | Weak transcription | HUES48 Cell Line | embryonic stem cell |
8 | chr2:210096800-210101000 | Weak transcription | iPS-18 Cell Line | embryonic stem cell |
9 | chr2:210096800-210101200 | Weak transcription | iPS-20b Cell Line | embryonic stem cell |
10 | chr2:210100800-210101600 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
11 | chr2:210101000-210101400 | Enhancers | H1 Cell Line | embryonic stem cell |
12 | chr2:210101000-210101600 | Enhancers | HUES48 Cell Line | embryonic stem cell |
13 | chr2:210101000-210101600 | Enhancers | iPS-18 Cell Line | embryonic stem cell |
14 | chr2:210101200-210101600 | Enhancers | iPS-20b Cell Line | embryonic stem cell |
15 | chr2:210101400-210101600 | Enhancers | ES-I3 Cell Line | embryonic stem cell |
16 | chr2:210101400-210102600 | Weak transcription | H1 Cell Line | embryonic stem cell |
17 | chr2:210101600-210102600 | Weak transcription | iPS-18 Cell Line | embryonic stem cell |
18 | chr2:210102600-210102800 | Enhancers | H1 Cell Line | embryonic stem cell |
19 | chr2:210102600-210102800 | Enhancers | iPS-18 Cell Line | embryonic stem cell |